Prescriber Information

Sativex^® is GW's lead cannabinoid pharmaceutical product, administered as an oral spray which is absorbed by the patient’s mouth.

In April 2005 GW received regulatory approval for Sativex in Canada for symptomatic relief of neuropathic pain in Multiple Sclerosis. In August 2007, Health Canada approved Sativex® as adjunctive analgesic treatment in patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Both approvals were secured under the Notice of Compliance with Conditions (NOC/c) policy.

Sativex is currently the subject of a regulatory submission in Europe for the treatment of MS spasticity. Sativex is also undergoing clinical trials in the United States as a potential treatment for cancer pain.

The current position regarding the availability of Sativex varies between different countries according to whether Sativex has been approved by the medical regulatory authority in the country and also on the local regulations regarding the prescribing of controlled drugs and unlicensed medicines.

If you would like to obtain further information on obtaining Sativex please click here.